Focal Segmental Glomerulosclerosis – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Owing to the various etiologies of the disease and differences in presentation, management of FSGS needs to be individualized. As the nephrotic syndrome increases the risk of worse outcomes, RAAS inhibitors are often initiated to reduce proteinuria and diuretics are commonly used for symptomatic benefit. Corticosteroid and immunosuppressive therapy (calcineurin inhibitors and antiproliferative agents) is also considered in FSGS associated with clinical features of the nephrotic syndrome. Immunosuppressive agents typically find use in patients for whom use of high-dose corticosteroid treatment is a concern, or where patients fail to respond to corticosteroid treatment. Using longitudinal claims data analysis, we demonstrate how FSGS is being treated in the United States and provide insights into what is driving prescribing practices.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed FSGS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed FSGS patients?
- How has tacrolimus been integrated into the treatment algorithm, and what is its source of business?
- What percentage of FSGS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of FSGS patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Table of contents
- Focal Segmental Glomerulosclerosis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms: Claims Data Analysis - FSGS - US - October 2019
Conor Walsh, Ph.D., M.Sc., is a senior director on the Cardiovascular, Metabolic, and Renal Disorders team at DRG, part of Clarivate. Prior to joining DRG, he worked at Medical Marketing Research International. Dr. Walsh holds an M.Sc. in bioinformatics and a Ph.D. in cardiac structural biology, both from the University of Manchester. For his doctoral work, he studied the molecular mechanisms underlying heart failure. He also holds a B.Sc. in biotechnology with first-class honors from the National University of Ireland in Galway.